Signaling Pathway Mediating Myeloma Cell Growth and Survival

por Hideshima, Teru, Anderson, Kenneth C.
Publicado 2021

The biological significance of histone modifiers in multiple myeloma: clinical applications

por Ohguchi, Hiroto, Hideshima, Teru, Anderson, Kenneth C.
Publicado 2018

PRMT5 inhibitors on the (myeloma) road

por Gulla, Annamaria, Hideshima, Teru, Anderson, Kenneth C.
Publicado 2018

Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications

por Ohguchi, Hiroto, Hideshima, Teru, Anderson, Kenneth C.
Publicado 2021

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma

por Hideshima, Teru, Raje, Noopur, Richardson, Paul G, Anderson, Kenneth C
Publicado 2008

IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells

por HIDESHIMA, HIROMASA, YOSHIDA, YASUHIRO, IKEDA, HIROSHI, HIDE, MAYA, IWASAKI, AKINORI, ANDERSON, KENNETH C., HIDESHIMA, TERU
Publicado 2014

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy

por Richardson, Paul, Mitsiades, Constantine, Laubach, Jacob, Schlossman, Robert, Ghobrial, Irene, Hideshima, Teru, Munshi, Nikhil, Anderson, Kenneth
Publicado 2010

Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways

por Hideshima, Teru, Ogiya, Daisuke, Liu, Jiye, Harada, Takeshi, Kurata, Keiji, Bae, Jooeun, Massefski, Walter, Anderson, Kenneth C
Publicado 2020

KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival

por Ohguchi, Hiroto, Harada, Takeshi, Sagawa, Morihiko, Kikuchi, Shohei, Tai, Yu-Tzu, Richardson, Paul G., Hideshima, Teru, Anderson, Kenneth C.
Publicado 2017

The Treatment of Multiple Myeloma Patients Not Eligible for Asct

por Richardson, Paul, Laubach, Jacob, Mahindra, Anuj, Mitsiades, Constantine, Schlossman, Robert, Ghobrial, Irene, Hideshima, Teru, Raje, Noopur, Munshi, Nikhil, Anderson., Kenneth
Publicado 2010

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer

por Hideshima, Teru, Mazitschek, Ralph, Qi, Jun, Mimura, Naoya, Tseng, Jen-Chieh, Kung, Andrew L., Bradner, James E., Anderson, Kenneth C.
Publicado 2017

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications

por Harada, Takeshi, Ohguchi, Hiroto, Grondin, Yohann, Kikuchi, Shohei, Sagawa, Morihiko, Tai, Yu-Tzu, Mazitschek, Ralph, Hideshima, Teru, Anderson, Kenneth C.
Publicado 2017

Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer

por Hideshima, Teru, Mazitschek, Ralph, Qi, Jun, Mimura, Naoya, Tseng, Jen-Chieh, Kung, Andrew L., Bradner, James E., Anderson, Kenneth C.
Publicado 2021

Bortezomib in the management of multiple myeloma

por Laubach, Jacob P, Mitsiades, Constantine S, Hideshima, Teru, Schlossman, Robert, Chauhan, Dharminder, Munshi, Nikhil, Ghobrial, Irene, Carreau, Nicole, Anderson, Kenneth C, Richardson, Paul G
Publicado 2009

Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma

por Jakubikova, Jana, Cholujova, Danka, Beke, Gabor, Hideshima, Teru, Klucar, Lubos, Leiba, Merav, Jamroziak, Krzysztof, Richardson, Paul G., Kastritis, Efstathios, Dorfman, David M., Anderson, Kenneth C.
Publicado 2023

A Novel Role for CCL3 (MIP-1α) in Myeloma-induced Bone Disease via Osteocalcin Downregulation and Inhibition of Osteoblast Function

por Vallet, Sonia, Pozzi, Samantha, Patel, Kishan, Vaghela, Nileshwari, Fulciniti, MariaTeresa, Veiby, Petter, Hideshima, Teru, Santo, Loredana, Cirstea, Diana, Scadden, David T, Anderson, Kenneth C, Raje, Noopur
Publicado 2011

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma

por Bae, Jooeun, Accardi, Fabrizio, Hideshima, Teru, Tai, Yu-Tzu, Prabhala, Rao, Shambley, Aaron, Wen, Kenneth, Rowell, Sean, Richardson, Paul G., Munshi, Nikhil C., Anderson, Kenneth C.
Publicado 2021

BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma

por Kurata, Keiji, Samur, Mehmet K., Liow, Priscilla, Wen, Kenneth, Yamamoto, Leona, Liu, Jiye, Morelli, Eugenio, Gulla, Annamaria, Tai, Yu-Tzu, Qi, Jun, Hideshima, Teru, Anderson, Kenneth C.
Publicado 2023

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma

por Adamia, Sophia, Bhatt, Shruti, Wen, Kenneth, Chyra, Zuzana, Fell, Geoffrey G., Tai, Yu-Tzu, Pioso, Marisa S., Abiatari, Ivane, Letai, Anthony, Dorfman, David M., Hideshima, Teru, Anderson, Kenneth C.
Publicado 2022

Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma

por Adamia, Sophia, Bhatt, Shruti, Wen, Kenneth, Chyra, Zuzana, Fell, Geoffrey G., Tai, Yu-Tzu, Pioso, Marissa S., Abiatari, Ivane, Letai, Anthony, Dorfman, David M., Hideshima, Teru, Anderson, Kenneth C.
Publicado 2022